Investors view Race Oncology’s latest release in a positive light.
The post Why did the Race Oncology share price rocket 10% today? appeared first on The Motley Fool Australia. –
The Race Oncology Ltd (ASX: RAC) share price flew higher today following a positive announcement by the pharmaceutical company.
At Tuesdayâs market close, Race Oncology shares ended the day up 9.90% to $1.665.
Letâs take a look at what the company updated the ASX with.
Race Oncology highlights peer review research poster abstracts
In its statement, Race Oncology advised that in the scientific journal, Cancer Research, two peer review abstracts have been published. This comes after a recent presentation was given at the American Association of Cancer Research (AACR) Annual Conference in April.
In the publication, both abstracts detail the new preclinical data on the anti-cancer uses of Zantrene.
The first abstract notes:
Conclusion: Through a comprehensive mechanistic analysis we explicitly demonstrate the biological and functional significance of FTO in governing PC [pancreatic cancer] tumorigenesis and maintenance of CSC; thus, targeting FTO may represent an attractive therapeutic approach for PC.
This describes preclinical data demonstrating Zantreneâs ability to inhibit FTO and suppress pancreatic carcinogenesis via targeting cancer stem cell maintenance.
FTO refers to the fat mass and obesity-associated (FTO) gene, which mostly influences the body mass index (BMI).
Pancreatic cancer is the third leading cause of cancer death and has few effective treatment options available on the market.
The second abstract states:
Conclusion: Our study establishes the functional importance of FTO in CRC [colorectal cancer] and provides novel evidence for the potential use of FTO inhibitor as an adjunctive treatment to 5FU based chemotherapy for CRC patientsâ.
The above paragraph explores the use of Zantrene as another treatment to be used together with the primary treatment.
This helps overcome colorectal cancer resistance to 5-FU based chemotherapy via inhibition of FTO in both cell and mouse models. Currently, resistance to 5-FU is a significant clinical issue as this drug remains a backbone of colorectal cancer treatment.
5-FU is a chemotherapy drug that is designed to slow the growth of cancer cells. This medicine is used to treat a number of cancers such as colon or rectal cancer, pancreatic cancer and more.
What did management say?
Race Oncology chief science officer, Dr Daniel Tillett commented:
This very promising research further highlights the emergence of Zantrene as an exquisitely potent inhibitor of FTO â one of the central genes in the proliferation of many cancers.
We are excited to see interest and use of Zantrene build, thanks to the efforts of great researchers like our collaborator Professor Chen and his colleagues.
Race Oncology share price review
Despite todayâs strong gains, the Race Oncology share price has lost 55% over the past 12 months.
Year-to-date has fared no better, down 53% for the 6 months so far.
Based on todayâs price, Race Oncology has aÂ market capitalisationÂ of about $241.67 million.
The post Why did the Race Oncology share price rocket 10% today? appeared first on The Motley Fool Australia.
Before you consider Race Oncology Limited, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Race Oncology Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of January 13th 2022
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.